NetworkNewsBreaks – Why Aditxt Inc. (NASDAQ: ADT
Post# of 111
(Total Views: 209)
Posted On: 05/27/2022 4:37:55 PM
NetworkNewsBreaks – Why Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’
Aditxt (NASDAQ: ADTX) is a biotech company commercializing new innovations. The company’s first commercial product, AditxtScore(TM), is an immune mapping technology designed to provide a personalized, comprehensive profile of an individual’s immune system. “The company’s first commercial application of the platform, AditxtScore(TM) for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances,” a recent article reads. Aditxt’s second innovation is a preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy(TM) (“ADi(TM)”), which aims to retrain the immune system to induce tolerance and address disease-causing immune responses while maintaining the ability to combat pathogenic infections. Aditxt is currently developing ADi(TM) products for psoriasis, type 1 diabetes and skin grafting.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Aditxt (NASDAQ: ADTX) is a biotech company commercializing new innovations. The company’s first commercial product, AditxtScore(TM), is an immune mapping technology designed to provide a personalized, comprehensive profile of an individual’s immune system. “The company’s first commercial application of the platform, AditxtScore(TM) for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances,” a recent article reads. Aditxt’s second innovation is a preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy(TM) (“ADi(TM)”), which aims to retrain the immune system to induce tolerance and address disease-causing immune responses while maintaining the ability to combat pathogenic infections. Aditxt is currently developing ADi(TM) products for psoriasis, type 1 diabetes and skin grafting.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)ADiTx Therapeutics Inc. (ADTX) Stock Research Links
Scroll down for more posts ▼